For patients with newly diagnosed Crohn’s disease, a “top-down” treatment strategy using anti-TNF biosimilar medication was less costly and more effective than an “accelerated step-up” strategy over a 5-year time horizon (Table 1). Here, TNF is linked to Crohn disease.